Heparin-induced thrombocytopenia - Alternative anticoagulation in pregnancy and lactation

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 5, 2002, Pages 439-445

  Lindhoff Last, Edelgard ^a   Bauersachs, Rupert ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Danaparoid; Heparin induced thrombocytopenia; Hirudin; Lactation; Pregnancy

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; DANAPAROID; HEPARIN; PHENPROCOUMON; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR; WARFARIN;

ADULT; ANIMAL MODEL; ANTICOAGULANT THERAPY; CENTRAL NERVOUS SYSTEM MALFORMATION; DRUG INDICATION; FEMALE; HUMAN; LACTATION; LOW BIRTH WEIGHT; NONHUMAN; OPTIC NERVE ATROPHY; PREGNANCY; PRIORITY JOURNAL; RABBIT; REVIEW; SPONTANEOUS ABORTION; STILLBIRTH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; ANTICOAGULANTS; CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG COMBINATIONS; FEMALE; HEPARIN; HEPARITIN SULFATE; HUMANS; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOCYTOPENIA; WARFARIN;

EID: 0036802413     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35284     Document Type: Review

References (50)

1. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996;335:108-114
2. Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997;24:499-521
3. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998;114:524-530
4. Brenner B. Inherited thrombophilia and fetal loss. Curr Opin Hematol 2000;7:290-295
5. Warkentin TE, Sheppard JAI, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-1708
6. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker; 2000:43-81
7. Van der Weyden MB, Hunt H, McGrath K, et al. Delayed-onset heparin-induced thrombocytopenia. A potentially malignant syndrome. Med J Aust 1983;2:132-135
8. Meytes D, Ayalon H, Virag I, Weisbort Y, Zakut H. Heparin-induced thrombocytopenia and recurrent thrombosis in pregnancy. A case report. J Reprod Med 1986;31:993-996
9. Henny CP, ten Cate H, ten Cate JW, et al. Thrombosis prophylaxis in an AT III deficient pregnant woman: Application of a low molecular weight heparinoid. Thromb Haemost 1986;55:301 (Letter)
10. Copplestone A, Oscier DG. Heparin-induced thrombocytopenia in pregnancy. Br J Haematol 1987;65:248 (Letter)
11. Van Besien K, Hoffman R, Golichowski A. Pregnancy associated with lupus anticoagulant and heparin-induced thrombocytopenia: Management with a low molecular weight heparinoid. Thromb Res 1991;62:23-29
12. Greinacher A, Eckhardt T, Mussmann J, Mueller-Eckhardt C. Pregnancy complicated by heparin associated thrombocytopenia: Management by a prospectively in vitro selected heparinoid (Org 10172). Thromb Res 1993;71:123-126
13. Gill J, Kovacs MJ. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol 1997;90:648-650
14. Boshkov LK, Hamilton P, Lee A, Boldt K. Successful therapy of heparin-induced thrombocytopenia with thrombosis (HITTS) in pregnancy with danaparoid sodium (Orgaran). Blood 1999;94(Suppl 1):102b (Abst)
15. Macchi L, Sarfati R, Guicheteau M, et al. Thromboembolic prophylaxis with danaparoid (Orgaran) in a high-thrombosisrisk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease. Clin Appl Thromb Hemost 2000;6:187-189
16. Taylor AA. Successful use of heparinoids in a pregnancy complicated by allergy to heparin. Br J Obstet Gynaecol 2001;108:1011-1012
17. Huhle G, Geberth M, Hoffmann U, Heene DL, Harenberg J. Management of heparin-induced thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 2000;49:67-69
18. Bartz C, Rath W. R-hirudin plasma levels are not affected by pregnancy. Int Angiol 2001;20:11 (Abst)
19. Calhoun BC, Hesser JW. Heparin-associated antibody with pregnancy: Discussion of two cases. Am J Obstet Gynecol 1987;156:964-966
20. Lindhoff-Last E, Willeke A, Thalhammer C, Bauersachs R. Hirudin treatment in a breastfeeding woman. Lancet 2000;355:467-468
21. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
22. Chong BH. Low molecular weight heparinoid and heparin-induced thrombocytopenia. Aust NZ J Med 1996;26:331 (Abst)
23. Magnani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997;8:74-81
24. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99:73-80
25. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593
26. Lewis BE, Wallis DE, Berkowith SD, et al for the ARG-911 Study investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843
27. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: An overview. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker; 2000:261-290
28. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-812
29. Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992;22:58-65
30. Vun CH, Evans S, Chong BH. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res 1996;81:525-532
31. Newman PM, Swanson RL, Chong BH. IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292-297
32. Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992;22:73-84
33. Peeters LLH, Hobbelen PMJ, Verkeste CM, et al. Placental transfer of Org 10172, a low molecular weight heparinoid, in the awake late-pregnant guinea pig. Thromb Res 1986;44:277-283
34. Harrison SJ, Rafferty I, McColl MD. Management of heparin allergy during pregnancy with danaparoid. Blood Coagul Fibrinolysis 2001;12:157-159
35. Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker; 2000:313-339
36. Weitz JI, Hudoba M, Massel D, Marganore J, Hirsh, J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391
37. Markwardt F, Fink G, Kaiser B, et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988;43:202-207
38. Huhle G, Song X, Wang LC, Hoffman U, Harenberg J. Generation and disappearance of antihirudin antibodies during treatment with r-hirudin. Fibrinolysis Proteolysis 1998;12:91-113
39. Pötzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920-925
40. Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 2000;100:55-60
41. Harenberg J, Hoffmann U, Liebe V, et al. Treatment of a woman with a lupus syndrome and cutaneous allergy to heparins/heparinoids by subcutaneous r-hirudin throughout pregnancy. Ann Hematol 2001;80:87 (Abst)
42. Aijaz A, Nelson J, Naseer N. Management of heparin allergy in pregnancy. Am J Hematol 2001;67:268-269
43. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1998;114:445-469
44. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122-140
45. Ginsberg JS, Hirsh J, Turner C, Levine N, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197-203
46. Chan WS, Anana S, Ginsberg J. Anticoagulation in women with mechanical heart valves. A systematic review of the literature. Arch Intern Med 2000;160:191-196
47. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119:122-131
48. Clark SI, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet Gynecol 2000;95:938-940
49. Le Orme ML, Lewis J, de Swiet M, et al. May mothers given warfarin breast-feed their infants? BMJ 1977;1:1564-1565
50. McKenna R, Cole BR, Vasan U. Is warfarin sodium contraindicated in the lactating mother? Pediatrics 1983;103:325-327